Please try another search
Voluntis S.A. develops digital therapeutic solutions for diabetes, oncology, and other therapeutic areas in France and the United States. It offers Insulia, a prescription medical device that provides automated basal insulin dose recommendations and coaching messages for people with type 2 diabetes; and Diabeo, a digital solution for type 1 and type 2 patients treated on a basal-bolus insulin regimen, which suggests insulin dosage, through algorithmic calculations that are specific to the patient and based on their particular doses. The company provides Oleena, a first FDA class II software-as-a-medical device for cancer indications; AstraZeneca, an e-Cediranib Olaparib application designed for patient self-reporting and management of hypertension and diarrhea; Theraxium Oncology, a cornerstone software platform for all digital therapeutics of cancer treatment, as well as coagulation and hemophilia solutions. Voluntis S.A. has a collaboration agreement with Bristol-Myers Squibb Company to co-develop digital Therapeutics for Oncology. Voluntis S.A. was founded in 2001 and is based in Suresnes, France. Voluntis S.A. operates as a subsidiary of AptarGroup, Inc.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review